VANCOUVER, Jan. 26 /PRNewswire-FirstCall/ -- InNexus Biotechnology, Inc. (the "Company") is pleased to announce that its shares have been listed on the NASD OTC Bulletin Board under the symbol "IXSBF". The Company's market-maker is Brean Murray & Co., Inc. of New York, NY.
InNexus is a reporting issuer with the United States Securities and Exchange Commission under Section 12(g) of the Securities Exchange Act of 1934. The Company's Registration Statement and filings can be viewed at http://www.sec.gov/.
InNexus will continue to trade on the TSX Venture Exchange under the symbol "IXS".
InNexus is developing the next generation of therapeutic, monoclonal antibodies using its SuperAntibody Technology Platform. InNexus intends to apply this technology to improve the potency of existing antibody products while opening new markets and disease applications with other forms of SuperAntibodies. InNexus will develop the technology through partnerships with biotechnology and pharmaceutical companies while pursuing development of its own products for unmet medical needs. To learn more about InNexus please visit the Company's website: http://www.innexusbiotech.com/
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not historical facts and are subject to risks and uncertainties which could cause actual results and the timing of certain events to differ materially from those set forth in or implied herein including, without limitation, risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims litigation and other risks associated with the Company's proposed activities.
On behalf of the Board of Directors of InNexus Biotechnology Inc.
Dr. A. Charles Morgan
Toll-free: 1-866-990-8382 or 1-888-271-0788
The TSX Venture Exchange has neither approved nor disapproved of
the information contained herein.
InNexus Biotechnology, Inc.
CONTACT: Investor Relations: Toll-free: 1-866-990-8382 or1-888-271-0788, email@example.com